Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-κB signaling pathway

Inflammation

Volumn 36, Issue 6, 2013, Pages 1201-1208

  Li, Xu ^a   Li, Zhiliang ^a   Zheng, Zhen ^a   Liu, Yina ^a   Ma, Xiaochun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

acute lung injury; endotoxemia; lipopolysaccharide; nuclear factor B; unfractionated heparin

Indexed keywords

CYTOKINE; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; LUNG EDEMA; LUNG INJURY; MALE; NONHUMAN; PNEUMONIA; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACUTE LUNG INJURY; ANIMALS; DOWN-REGULATION; ENDOTOXEMIA; HEPARIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MALE; NF-KAPPA B; PNEUMONIA; RATS; RATS, WISTAR; SEPSIS;

EID: 84888146447     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9656-5     Document Type: Article

References (28)

1. MacLaren, R., and K.A. Stringer. 2007. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 27(6): 860-873.
2. Cepkova, M., and M.A. Matthay. 2006. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. Journal of Intensive Care Medicine 21: 119-143.
3. Frutos-Vivar, F., N.D. Ferguson, and A. Esteban. 2006. Epidemiology of acute lung injury and acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 327-336.
4. Rubenfeld, G.D., E. Caldwell, E. Peabody, et al. 2005. Incidence and outcomes of acute lung injury. The New England Journal of Medicine 353: 1685-1693.
5. Ware, L.B., E. Camerer, K.E. Welty-Wolf, et al. 2006. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 291(3): L307-L311.
6. Bastarache, J.A., L.B. Ware, and G.R. Bernard. 2006. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 365-376.
7. Schultz, M.J., J.J. Haitsma, H. Zhang, et al. 2006. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Critical Care Medicine 34: 871-877.
8. Sapru, A., J.L. Wiemels, J.S. Witte, et al. 2006. Acute lung injury and the coagulation pathway: potential role of gene polymorphisms in the protein C and fibrinolytic pathways. Intensive Care Medicine 32(9): 1293-1303.
9. Welty-Wolf, K.E., M.S. Carraway, T.L. Ortel, et al. 2006. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L21-L31.
10. Maybauer, M.O., D.M. Maybauer, J.F. Fraser, et al. 2006. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Critical Care Medicine 34(9): 2432-2438.
11. Yasui, H., E.C. Gabazza, S. Tamaki, et al. 2001. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. American Journal of Respiratory and Critical Care Medicine 163: 1660-1668.
12. Uchiba, M., K. Okajima, K. Murakami, et al. 1996. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. American Journal of Physiology 271: L470-L475.
13. Harada, N., K. Okajima, and M. Uchiba. 2006. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Critical Care Medicine 34: 1883-1891.
14. Yagmurdur, M.C., E. Turk, G. Moray, et al. 2005. Effect of heparin on bacterial translocation and gut epithelial apoptosis after burn injury in the rat: dose-dependent inhibition of the complement cascade. Burns 31: 603-609.
15. Matzner, Y., G. Marx, R. Drexler, et al. 1984. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thrombosis and Haemostasis 52: 134-137.
16. Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
17. Zingarelli, B. 2005. Nuclear factor-kappaB. Critical Care Medicine 33: S414-S416.
18. Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622-L645.
19. Grisham, M.B., L.A. Hernandez, and D.N. Granger. 1986. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. American Journal of Physiology 251: G567-G574.
20. Smith, K.M., J.D. Mrozek, S.C. Simonton, et al. 1997. Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory distress syndrome. Critical Care Medicine 25: 1888-1897.
21. Gando, S. 2010. Microvascular thrombosis and multiple organ dysfunction syndrome. Critical Care Medicine 38(2): S35-S42.
22. Schwartz, M.D., E.E. Moore, F.A. Moore, et al. 1996. Nuclear factor-kappaB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Critical Care Medicine 24(8): 1285-1292.
23. Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202: 145-156.
24. Tyrell, D.J., S. Kilfeather, and C.P. Page. 1995. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends in Pharmacological Sciences 16: 198-204.
25. Morrison, A.M., P. Wang, and I.H. Chaudry. 1996. A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis. Shock 6: 46-51.
26. Li, X., Z. Zheng, X. Li, et al. 2012. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 60(1): 114-121.
27. Cinel, I., and R.P. Dellinger. 2007. Advances in pathogenesis and management of sepsis. Current Opinion in Infectious Diseases 20: 345-352.
28. Li, X., Z. Zheng, Y.R. Mao, et al. 2012. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thrombosis Research 129(5): e223-e228.